Connection

Denis Guttridge to Mice

This is a "connection" page, showing publications Denis Guttridge has written about Mice.
Connection Strength

1.631
  1. Modeling Human Cancer-induced Cachexia. Cell Rep. 2019 08 06; 28(6):1612-1622.e4.
    View in: PubMed
    Score: 0.073
  2. NF-?B inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model. Nat Commun. 2018 08 24; 9(1):3431.
    View in: PubMed
    Score: 0.068
  3. NF-?B regulates GDF-15 to suppress macrophage surveillance during early tumor development. J Clin Invest. 2017 Oct 02; 127(10):3796-3809.
    View in: PubMed
    Score: 0.064
  4. MyoD Regulates Skeletal Muscle Oxidative Metabolism Cooperatively with Alternative NF-?B. Cell Rep. 2016 10 04; 17(2):514-526.
    View in: PubMed
    Score: 0.060
  5. Analysis of Aerobic Respiration in Intact Skeletal Muscle Tissue by Microplate-Based Respirometry. Methods Mol Biol. 2016; 1460:337-43.
    View in: PubMed
    Score: 0.057
  6. A TGF-? pathway associated with cancer cachexia. Nat Med. 2015 Nov; 21(11):1248-9.
    View in: PubMed
    Score: 0.056
  7. NF-?B functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep. 2014 Oct 09; 9(1):90-103.
    View in: PubMed
    Score: 0.052
  8. NF-?B-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. 2013 Nov; 123(11):4821-35.
    View in: PubMed
    Score: 0.049
  9. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal. 2013 Jul 30; 6(286):ra63.
    View in: PubMed
    Score: 0.048
  10. IKKa and alternative NF-?B regulate PGC-1? to promote oxidative muscle metabolism. J Cell Biol. 2012 Feb 20; 196(4):497-511.
    View in: PubMed
    Score: 0.043
  11. Detection of NF-?B activity in skeletal muscle cells by electrophoretic mobility shift analysis. Methods Mol Biol. 2012; 798:505-16.
    View in: PubMed
    Score: 0.043
  12. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One. 2010 Aug 30; 5(8):e12479.
    View in: PubMed
    Score: 0.039
  13. NF-kappaB functions in stromal fibroblasts to regulate early postnatal muscle development. J Biol Chem. 2010 Feb 19; 285(8):5479-87.
    View in: PubMed
    Score: 0.037
  14. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep. 2009 Nov; 10(11):1272-8.
    View in: PubMed
    Score: 0.037
  15. The RelA/p65 subunit of NF-kappaB specifically regulates cyclin D1 protein stability: implications for cell cycle withdrawal and skeletal myogenesis. J Cell Biochem. 2009 Jan 01; 106(1):42-51.
    View in: PubMed
    Score: 0.035
  16. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008 Nov 04; 14(5):369-81.
    View in: PubMed
    Score: 0.035
  17. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol. 2008 Feb 25; 180(4):787-802.
    View in: PubMed
    Score: 0.033
  18. Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int Rev Immunol. 2008; 27(5):375-87.
    View in: PubMed
    Score: 0.033
  19. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol. 2007 Jun; 27(12):4374-87.
    View in: PubMed
    Score: 0.031
  20. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 2007 Apr; 117(4):889-901.
    View in: PubMed
    Score: 0.031
  21. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005 Nov; 8(5):421-32.
    View in: PubMed
    Score: 0.028
  22. RelA/p65 regulation of IkappaBbeta. Mol Cell Biol. 2005 Jun; 25(12):4956-68.
    View in: PubMed
    Score: 0.027
  23. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004 Aug; 114(3):370-8.
    View in: PubMed
    Score: 0.026
  24. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003 Jan 24; 278(4):2294-303.
    View in: PubMed
    Score: 0.023
  25. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life Sci Alliance. 2022 11; 5(11).
    View in: PubMed
    Score: 0.022
  26. Extracellular vesicles derived from tumour cells as a trigger of energy crisis in the skeletal muscle. J Cachexia Sarcopenia Muscle. 2022 02; 13(1):481-494.
    View in: PubMed
    Score: 0.021
  27. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000 Sep 29; 289(5488):2363-6.
    View in: PubMed
    Score: 0.020
  28. The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damage. Proc Natl Acad Sci U S A. 2019 09 03; 116(36):17980-17989.
    View in: PubMed
    Score: 0.018
  29. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999 Aug; 19(8):5785-99.
    View in: PubMed
    Score: 0.018
  30. Requirement for NF-?B in maintenance of molecular and behavioral circadian rhythms in mice. Genes Dev. 2018 11 01; 32(21-22):1367-1379.
    View in: PubMed
    Score: 0.017
  31. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Res. 2018 12 01; 78(23):6680-6690.
    View in: PubMed
    Score: 0.017
  32. SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-?B and interferon pathways. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):E3798-E3807.
    View in: PubMed
    Score: 0.017
  33. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer. 2018 Feb; 65(2).
    View in: PubMed
    Score: 0.016
  34. Thrombin causes a marked delay in skeletal myogenesis that correlates with the delayed expression of myogenin and p21CIP1/WAF1. J Biol Chem. 1997 Sep 26; 272(39):24117-20.
    View in: PubMed
    Score: 0.016
  35. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
    View in: PubMed
    Score: 0.016
  36. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 02; 16(2):344-356.
    View in: PubMed
    Score: 0.015
  37. ?Np63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget. 2016 Jul 26; 7(30):48533-48546.
    View in: PubMed
    Score: 0.015
  38. Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer Discov. 2016 09; 6(9):1036-51.
    View in: PubMed
    Score: 0.015
  39. Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-?B Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic Function. Int J Mol Sci. 2016 Mar 01; 17(3):323.
    View in: PubMed
    Score: 0.014
  40. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther. 2016 05; 15(5):1018-28.
    View in: PubMed
    Score: 0.014
  41. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-?B-dependent Manner. Cancer Cell. 2016 Feb 08; 29(2):201-13.
    View in: PubMed
    Score: 0.014
  42. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. J Natl Cancer Inst. 2015 Dec; 107(12):djv274.
    View in: PubMed
    Score: 0.014
  43. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 2015 Nov; 29(11):4544-54.
    View in: PubMed
    Score: 0.014
  44. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014 Mar 25; 111(12):4525-9.
    View in: PubMed
    Score: 0.013
  45. Microglia induce motor neuron death via the classical NF-?B pathway in amyotrophic lateral sclerosis. Neuron. 2014 Mar 05; 81(5):1009-1023.
    View in: PubMed
    Score: 0.012
  46. Regulation of skeletal muscle oxidative phenotype by classical NF-?B signalling. Biochim Biophys Acta. 2013 Aug; 1832(8):1313-25.
    View in: PubMed
    Score: 0.012
  47. NF-?B inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest. 2012 Jul; 122(7):2601-12.
    View in: PubMed
    Score: 0.011
  48. IKKa-mediated signaling circuitry regulates early B lymphopoiesis during hematopoiesis. Blood. 2012 Jun 07; 119(23):5467-77.
    View in: PubMed
    Score: 0.011
  49. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther. 2012 Jun; 20(6):1222-33.
    View in: PubMed
    Score: 0.011
  50. M-CSF induces monocyte survival by activating NF-?B p65 phosphorylation at Ser276 via protein kinase C. PLoS One. 2011; 6(12):e28081.
    View in: PubMed
    Score: 0.011
  51. NF-?B negatively impacts the myogenic potential of muscle-derived stem cells. Mol Ther. 2012 Mar; 20(3):661-8.
    View in: PubMed
    Score: 0.011
  52. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011; 6(7):e22538.
    View in: PubMed
    Score: 0.010
  53. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011 Aug 01; 71(15):5101-10.
    View in: PubMed
    Score: 0.010
  54. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011; 63(5):749-62.
    View in: PubMed
    Score: 0.010
  55. Systemic delivery of NEMO binding domain/IKK? inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis. 2011 Sep; 43(3):598-608.
    View in: PubMed
    Score: 0.010
  56. Improvement of cardiac contractile function by peptide-based inhibition of NF-?B in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med. 2011 May 17; 9:68.
    View in: PubMed
    Score: 0.010
  57. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin Cancer Res. 2011 May 01; 17(9):2757-66.
    View in: PubMed
    Score: 0.010
  58. Peptide-based inhibition of NF-?B rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med. 2011 May-Jun; 17(5-6):508-15.
    View in: PubMed
    Score: 0.010
  59. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol. 2011 Mar; 69(3):540-52.
    View in: PubMed
    Score: 0.010
  60. Inhibition of the IKK/NF-?B pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther. 2010 Dec; 17(12):1476-83.
    View in: PubMed
    Score: 0.010
  61. Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-kappaB. Am J Physiol Lung Cell Mol Physiol. 2010 Jun; 298(6):L744-54.
    View in: PubMed
    Score: 0.009
  62. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer. 2009 Aug; 53(2):136-44.
    View in: PubMed
    Score: 0.009
  63. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009 Aug 11; 106(32):13433-8.
    View in: PubMed
    Score: 0.009
  64. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res. 2008 Oct 15; 68(20):8351-60.
    View in: PubMed
    Score: 0.009
  65. Immunocompetent murine model of cancer cachexia for head and neck squamous cell carcinoma. Head Neck. 2008 Mar; 30(3):320-6.
    View in: PubMed
    Score: 0.008
  66. Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2. Int J Cancer. 2008 Mar 01; 122(5):978-89.
    View in: PubMed
    Score: 0.008
  67. Comparison of animal models for head and neck cancer cachexia. Laryngoscope. 2007 Dec; 117(12):2152-8.
    View in: PubMed
    Score: 0.008
  68. The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1263-9.
    View in: PubMed
    Score: 0.008
  69. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol. 2007 Nov 15; 179(10):7121-7.
    View in: PubMed
    Score: 0.008
  70. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia. 2007 Aug; 21(8):1752-62.
    View in: PubMed
    Score: 0.008
  71. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J Immunol. 2006 Apr 15; 176(8):4979-86.
    View in: PubMed
    Score: 0.007
  72. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol. 2004 Jul; 24(13):5721-32.
    View in: PubMed
    Score: 0.006
  73. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem. 2001 Oct 19; 276(42):39259-63.
    View in: PubMed
    Score: 0.005
  74. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol. 2000 Mar; 20(5):1626-38.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.